4/18
09:11 am
nrsn
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting [Yahoo! Finance]
Low
Report
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting [Yahoo! Finance]
4/18
08:30 am
nrsn
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Medium
Report
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
4/12
08:36 am
nrsn
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 [Yahoo! Finance]
Medium
Report
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 [Yahoo! Finance]
4/12
08:30 am
nrsn
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Medium
Report
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
4/10
07:21 pm
nrsn
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement [Yahoo! Finance]
Low
Report
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement [Yahoo! Finance]
4/10
07:16 pm
nrsn
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
Low
Report
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
4/9
08:49 am
nrsn
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics [Yahoo! Finance]
Medium
Report
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics [Yahoo! Finance]
4/9
08:30 am
nrsn
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
Low
Report
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
4/5
09:44 am
nrsn
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update [Yahoo! Finance]
4/5
09:29 am
nrsn
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
High
Report
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
2/21
08:44 am
nrsn
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial [Yahoo! Finance]
Low
Report
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial [Yahoo! Finance]
2/21
08:30 am
nrsn
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
High
Report
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
2/7
09:36 am
nrsn
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule [Yahoo! Finance]
Low
Report
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule [Yahoo! Finance]
2/7
09:27 am
nrsn
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
Low
Report
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
1/30
08:43 am
nrsn
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 [Yahoo! Finance]
Medium
Report
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 [Yahoo! Finance]
1/30
08:30 am
nrsn
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Low
Report
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024